Mankind Pharma and Innovent Biologics have partnered to exclusively license and commercialise innovative immunotherapy drug Sintilimab, used in the treatment of cancer, in the Indian market. This strategic collaboration aims to address the critical challenges in cancer treatment and improve patient access to innovative therapeutic options in the region.
Mankind Pharma is engaged in developing, manufacturing and marketing a diverse range of pharmaceutical formulations across various acute and chronic therapeutic areas, as well as several consumer healthcare products.
